Biological agents for anti-tumor necrosis factor-α therapy have revolutionized treatments for autoimmune diseases; however, approximately 20% of rheumatology and 40% of gastroenterology patients do not respond to the therapy, or they show reduced drug efficacy because of anti-drug antibody (ADA) formation.
The New Test for Monitoring Infliximab Therapy: From Laboratory to Clinical Practice / De Santis, Elena; Melegari, Alessandra; Bonaguri, Chiara; Sandri, Gilda; Mascia, Maria Teresa; Gaiani, Federica; Pecoraro, Valentina; De Angelis, Gianluigi; Trenti, Tommaso. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - 20:2(2018), pp. 91-94.
The New Test for Monitoring Infliximab Therapy: From Laboratory to Clinical Practice
Sandri, Gilda;Mascia, Maria Teresa;
2018
Abstract
Biological agents for anti-tumor necrosis factor-α therapy have revolutionized treatments for autoimmune diseases; however, approximately 20% of rheumatology and 40% of gastroenterology patients do not respond to the therapy, or they show reduced drug efficacy because of anti-drug antibody (ADA) formation.
| File | Dimensione | Formato | |
|---|---|---|---|
|
the new test for monitoring infliximab136225.pdf
Open access
Descrizione: articolo principale
Tipologia:
Versione pubblicata dall'editore
Dimensione
128.4 kB
Formato
Adobe PDF
|
128.4 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
